|
[1]
|
朱于坚. 肥胖2型糖尿病奥利司他治疗效果的初步观察[J]. 海峡药学, 2016, 28(6): 162-163.
|
|
[2]
|
中华医学会内分泌学分会. 中国2型糖尿病合并肥胖综合管理专家共识[J]. 糖尿病天地(临床), 2016, 10(9): 392-394.
|
|
[3]
|
American Diabetes Association (2019) Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care, 42, 81-89. [Google Scholar] [CrossRef]
|
|
[4]
|
Lim, E.L., Hollingsworth, K.G., Aribisala, B.S., et al. (2011) Reversal of Type 2 Diabetes: Normalization of Beta Cell Function in Association with Decreased Pancreas and Liver Triacylglycerol. Diabetologia, 54, 2506-2514. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Huang, X.Y., Chen, J.X., Ren, Y., et al. (2022) Exosomal miR-122 Promotes Adipogenesis and Aggravates Obesity through the VDR/SREBF1 Axis. Obesity (Silver Spring), 30, 666-679. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Lee, H.M., Wong, W.K., Fan, B.Q., et al. (2021) Detection of In-creased Serum miR-122-5p and miR-455-3p Levels before the Clinical Diagnosis of Liver Cancer in People with Type 2 Diabetes. Scientific Reports, 11, Article No. 23756. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Mohany, K.M., Al Rugaie, O., Al-Wutayd, O. and Al-Nafeesah, A. (2021) Investigation of the Levels of Circulating miR-29a, miR-122, Sestrin 2 and Inflammatory Markers in Obese Children with/without Type 2 Diabetes: A Case Control Study. BMC Endocrine Disorders, 21, Article No. 152. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
董敏. 利拉鲁肽对我国肥胖2型糖尿病患者减重治疗的现状及进展[J]. 天津药学, 2021, 33(5): 74-78.
|
|
[9]
|
Hulsmans, M., De Keyzer, D. and Holvoet, P. (2011) MicroRNAs Regulating Oxidative Stress and Inflammation in Relation to Obesity and Atherosclerosis. The FASEB Journal, 25, 2515-2527. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Kim, D. and Scherer, P.E. (2021) Obesity, Diabetes, and Increased Cancer Progression. Diabetes & Metabolism Journal, 45, 799-812. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
|
|
[12]
|
Shaw, J.E., Sicree, R.A. and Zimmet, P.Z. (2010) Global Estimates of the Prevalence of Diabetes for 2010 and 2030. DIABETES RES CLIN PR, 87, 4-14. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Ying, S.Y., Chang, D.C., Miller, J.D., et al. (2006) The Mi-croRNA: Overview of the RNA Gene That Modulates Gene Functions. In: Ying, S.Y., Ed., MicroRNA Protocols. Methods in Molecular Biology, Vol. 342, Humana Press, Totowa, 1-18. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Tanzer, A. and Stadler, P.F. (2006) Evolution of microRNAs. In: Ying, S.Y., Ed., MicroRNA Protocols. Methods in Molecular Biology, Vol. 342, Humana Press, Totowa, 335-350. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Fernandez-Valverde, S.L., Taft, R.J. and Mattick, J.S. (2011) Mi-croRNAs in β-Cellbiology, Insulin Resistance, Diabetes and Its Complications. Diabetes, 60, 1825-1831. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Fang, Q., Chen, W., Jian, Y.R., et al. (2022) Serum Expression Level of MicroRNA-122 and Its Significance in Patients with Hepatitis B Virus Infection. Journal of Healthcare Engineering, 2022, Article ID: 8430276. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
孟昶, 朱磊. miR-122对脂代谢影响的研究进展[J]. 辽宁体育科技, 2019, 41(2): 31-35. [Google Scholar] [CrossRef]
|
|
[18]
|
Refeat, M.M., Hassan, N.A.-M., Ahmad, I.H., et al. (2021) Correlation of Circulating miRNA-33a and miRNA-122 with Lipid Metabolism among Egyptian Patients with Metabolic Syndrome. Journal of Genetic Engineering and Biotechnology, 19, Article No. 147. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Benatti, R.O., Melo, A.M., Borges, F.O., et al. (2014) Maternal High-Fat Diet Consumption Modulates Hepatic Lipid Metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) Expression in Offspring. British Journal of Nutrition, 111, 2112-2122. [Google Scholar] [CrossRef]
|
|
[20]
|
Baselga, E.L., Blade, C., Ribas, L.A., et al. (2014) Chronic Sup-plementation of Proanthocyanidins Reduces Postprandial Lipemia and Liver miR-33a and miR-122 Levels in a Dose-Dependent Manner in Healthy Rats. The Journal of Nutritional Biochemistry, 25, 151-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
López-Pastor, A.R., Infante-Menéndez, J., González-Illanes, T., et al. (2021) Concerted Regulation of Non-Alcoholic Fatty Liver Disease Progression by microRNAs in Apolipoprotein E-Deficient Mice. Disease Models & Mechanisms, 14, Article ID: dmm049173. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Hu, Y.Y., Peng, X.T., Du, G.P., et al. (2022) MicroRNA-122-5p Inhi-bition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-Alcoholic Fatty Liver Disease through Targeting FOXO3. Front Physiol, 13, Article ID: 803445. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Zinkhan, E.K., Yu, B. and Schlegel, A. (2018) Prenatal Exposure to a Maternal High Fat Diet Increases Hepatic Cholesterol Accumulation in Intrauterine Growth Restricted Rats in Part through MicroRNA-122 Inhibition of Cyp7a1. Frontiers in Physiology, 9, 645. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Cirera, S., Birck, M., Busk, P.K., et al. (2010) Expression Profiles of miRNA-122 and Its Target CAT1 in Minipigs (Sus scrofa) Fed a High-Cholesterol Diet. Comparative Medicine, 60, 136-141.
|
|
[25]
|
Ghosh, J., Bose, M., Roy, S., et al. (2013) Leishmania Donovani Targets Dicerl to Downregulate miR-122, Lower Serum Cholesterol, and Facilitate Murine Liver Infection. Cell Host & Microbe, 13, 277-288. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Wu, G.Y., Rui, C., Chen, J.Q., et al. (2017) MicroRNA-122 In-hibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1. Cellular Physiology and Bio-chemistry, 44, 1651-1664. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Shukla, U., Tumma, N., Gratsch, T., et al. (2013) Insights into Insu-lin-Mediated Regulation of CYP2E1: miR-132/-212 Targeting of CYP2E1 and Role of Phosphatidylinositol 3-Kinase, Akt (Protein Kinase B), Mammalian Target of Rapamycin Signaling in Regulating miR-132/-212 and miR-122/-181a Ex-pression in Primary Cultured Rat Hepatocytes. Drug Metabolism and Disposition, 41, 1769-1777. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
陈丽霞, 张秀薇, 禤文婷, 等. miR-101、miR-122在妊娠期糖尿病患者血清和胎盘组织中表达及意义[J]. 广东医科大学学报, 2021, 39(3): 267-270.
|
|
[29]
|
魏胜男. 黄癸固体分散体通过调控肝脏HNF4α/miR-122通路纠正糖尿病糖脂代谢紊乱机制研究[D]: [博士学位论文]. 长春: 吉林大学, 2016.
|
|
[30]
|
Mahjoob, G., Ahmadi, Y., Fatima, R.H., et al. (2022) Circulating microRNAs as Predictive Biomarkers of Coronary Artery Diseases in Type 2 Diabetes Patients. Journal of Clinical Laboratory Analysis, 36, e24380. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Liu, X.H., Xu, H.L., Zang, Y.H., et al. (2022) Radix Rehmannia Glutinosa Inhibits the Development of Renal Fibrosis by Regulating miR-122-5p/PKM Axis. American Journal of Translational Research, 14, 103-119.
|
|
[32]
|
Cheng, L., Qiu, X.Y., He, L.Y., et al. (2022) MicroRNA-122-5p Ameliorates Tubular In-jury in Diabetic Nephropathy via FIH-1/HIF-1α Pathway. Renal Failure, 44, 293-303. [Google Scholar] [CrossRef]
|
|
[33]
|
Zang, L., Gao, F., Huang, A.J., et al. (2022) Icariin Inhibits Epithelial Mesenchymal Transition of Renal Tubular Epithelial Cells via Regulating the miR-122-5p/FOXP2 Axis in Di-abetic Nephropathy Rats. Journal of Pharmacological Sciences, 148, 204-213. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Pastukh, N., Meerson, A., Kalish, D., et al. (2019) Serum miR-122 Levels Correlate with Diabetic Retinopathy. Clinical and Experimental Medicine, 19, 255-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Li, K.L., Yan, G.H., Huang, H.J., et al. (2022) An-ti-Inflammatory and Immunomodulatory Effects of the Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells on Osteoarthritis via M2 Macrophages. Journal of Nanobiotechnology, 20, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
刘利慧, 周波, 王霜, 等. 伴腹型肥胖2型糖尿病患者胰岛素抵抗指数与脂肪细胞脂肪酸结合蛋、血尿酸水平密切相关[J]. 内科急危重症杂志, 2021, 27(4): 310-314.
|